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Introduction {#sec1}
============

The gastrointestinal tract is colonized by trillions of commensals and represents a substantial interface between the host immune system and the environment. The maintenance of this barrier requires immunological tolerance to beneficial microflora, while retaining the capacity to mount an inflammatory response to enteropathic organisms. Tissue-resident immune cells play a critical role in this process, carrying out diverse functions that are coordinated by complex inter-cellular signaling networks. Disruption of normal mucosal immune interactions is characteristic of inflammatory bowel disease (IBD), a chronic, relapsing condition that is increasing in frequency ([@bib28]). Intestinal macrophages form a central hub in this cellular network, with the ability to detect microbial and environmental stimuli and to produce cytokines and chemokines that drive local immune cells toward tolerance or inflammation ([@bib10]; [@bib26]).

Intestinal macrophages are largely replenished from circulating monocytes ([@bib2]), which during homeostasis, undergo tolerogenic programming upon entry into the intestine toward an interleukin (IL)-10-producing phenotype ([@bib4]; [@bib24]; [@bib78]). In contrast, during intestinal inflammation, infiltrating monocytes differentiate toward an inflammatory phenotype, characterized by an altered cytokine and chemokine profile and enhanced microbicidal activity ([@bib1]; [@bib77]). Although these inflammatory macrophages are important for defense against enteropathogens ([@bib55]), inappropriate macrophage activation is associated with tissue pathology in IBD and in murine models of colitis ([@bib6]; [@bib54]). However, the factors that promote inflammatory macrophage responses in the gut remain incompletely understood.

Recent studies have highlighted the importance of macrophage-derived cytokines such as IL-1β, IL-23, and TL1A in driving type 17 immune responses, including T helper 17 (Th17) cells and group 3 innate lymphoid cells (ILC3) ([@bib9]; [@bib33]; [@bib35]). In response to these cytokines, ILC3s in turn produce IL-22, promoting epithelial integrity and anti-microbial peptide (AMP) production to limit system bacterial spread following challenge with enteropathic bacteria ([@bib7]; [@bib52]; [@bib62]). ILC3s also produce granulocyte-macrophage colony stimulating factor (GM-CSF), stimulating tolerogenic dendritic cells (DC) that prime regulatory T cells to maintain intestinal homeostasis ([@bib39]). During intestinal inflammation, ILC3-derived GM-CSF can be pro-inflammatory, mobilizing and activating eosinophils ([@bib20], [@bib21]), enhancing neutrophil and monocyte recruitment ([@bib43]; [@bib61]), and controlling ILC3 migration ([@bib43]).

We have previously demonstrated that anti-microbial IgG is elevated during chronic intestinal inflammation and drives detrimental macrophage responses in the context of ulcerative colitis by cross-linking macrophage Fcγ receptors ([@bib6]). In order to discover additional factors that might promote inflammatory macrophage activation during intestinal inflammation, we investigated the transcriptome of intestinal macrophages in Crohn's disease patients and in a murine model of colitis. This identified GM-CSF as a critical regulator of macrophage activation in intestinal inflammation, which was primarily produced by innate lymphocytes, particularly ILC3s. In mouse models of intestinal infection and inflammation, we found that GM-CSF regulated the maturation and polarization of intestinal macrophages, preferentially inducing anti-microbial inflammatory M1 macrophages while suppressing a tissue-reparative macrophage phenotype. Its effects were protective during enteropathic infection with *Citrobacter rodentium* but resulted in pathological inflammation following mucosal barrier breach. We confirmed that ILC-derived GM-CSF enhanced macrophage microbicidal activity, while suppressing wound-healing transcriptional programs, including collagen and platelet-derived growth factor (PDGF) production, suggesting that some level of GM-CSF signaling may be potentially beneficial in limiting the development of intestinal fibrosis. Indeed, the transcriptional signature of macrophages isolated from ILC-depleted colons was significantly enriched in Crohn's disease biopsies obtained from patients with complicated disease, including those with stricturing disease. GM-CSF also reinforced mucosal type 17 immunity through increased production of ILC3- and Th17 cell-stimulating cytokines by macrophages, setting up a positive feedback loop to promote IL-22 secretion and epithelial AMP production. Together, our data reveal the importance of GM-CSF and ILC-macrophage signaling axis in calibrating macrophage polarization to augment anti-bacterial responses during infection and inflammation, while inhibiting the generation of pro-fibrotic macrophages.

Results {#sec2}
=======

GM-CSF Is an Upstream Regulator of Inflammatory Macrophage Function in the Intestine {#sec2.1}
------------------------------------------------------------------------------------

To identify candidate cytokines that might promote inflammatory macrophage function in the intestine, we assessed the transcriptional profile of flow-sorted colonic Ly6C^lo^ MHC-II^+^ macrophages ([Figure 1](#fig1){ref-type="fig"}A) isolated from healthy and inflamed mouse colon following DSS administration and applied Ingenuity Pathway Analysis (IPA). IPA is a powerful informatic tool that enables an unbiased assessment of phenotype-associated biological pathways in transcriptomic datasets ([@bib13]; [@bib34]). This identified several candidate regulators in inflamed macrophages ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Of these, GM-CSF was notable due to its high enrichment *Z* score and its proximal hierarchical location in the regulatory network, controlling the activation of several key cytokines including tumor necrosis factor (TNF) and IL-1β ([Figure 1](#fig1){ref-type="fig"}B). Indeed, predicted GM-CSF-regulated genes in DSS macrophages included those involved in inflammasome activation (*Il1b*, *Hif1a*, *Nlrp3*), prostaglandin E2 production (*Ptgs2*) and co-stimulation (*Cd40*, *Cd80*) ([Figure S1](#mmc1){ref-type="supplementary-material"}B), and GM-CSF receptor subunits (*Csf2ra*, *Csf2rb*, *Csf2rb2*) were highly expressed in murine colonic macrophages ([Figure S1](#mmc1){ref-type="supplementary-material"}C). To determine the relevance of these observations to human intestinal macrophages, we analyzed a recently published single cell RNA sequencing (scRNA-seq) study in ileal Crohn's disease ([@bib37]). Within the mononuclear phagocyte (MNP) cluster ([Figure S1](#mmc1){ref-type="supplementary-material"}D), we identified resident and inflammatory macrophage clusters ([Figure 1](#fig1){ref-type="fig"}C) based on canonical marker expression ([Figure S1](#mmc1){ref-type="supplementary-material"}E). Resident macrophages were enriched in uninflamed ileal biopsies, while inflammatory macrophages were almost entirely restricted to inflamed mucosa ([Figure 1](#fig1){ref-type="fig"}C). Application of IPA to this inflammatory macrophage dataset also identified GM-CSF as a candidate upstream regulator, with a similar dominant hierarchical position within the interaction network to that observed in DSS macrophages ([Figure 1](#fig1){ref-type="fig"}D). Together, these analyses suggest that GM-CSF is a critical modulator of inflammatory macrophage function in intestinal inflammation in humans and mice.Figure 1GM-CSF Is an Upstream Regulator of Inflammatory Macrophage Function in the Intestine(A) Schematic of colonic CX3CR1^+^ CD11b^+^ Ly6C^lo^ MHC-II^+^ macrophages from control or 2% DSS-treated C57BL/6 mice, analyzed by RNA-seq. Data derived from GEO: [GSE109040](ncbi-geo:GSE109040){#intref0315}.(B) GM-CSF-associated upstream regulatory network in DSS macrophages derived by ingenuity pathway analysis (IPA).(C) UMAP of human ileal resident and inflammatory macrophage subsets from Crohn's disease patients derived by scRNA-seq, showing tissue of origin. Data derived from GEO: [GSE134809](ncbi-geo:GSE134809){#intref0320}.(D) GM-CSF-associated upstream regulatory network in inflammatory macrophages derived by IPA.(E) Murine colonic ILC and T cell gating strategy.(F) Intracellular GM-CSF staining for colonic ILC and T cell subsets between control (n = 5) and 2% DSS-treated (n = 5) C57BL/6 mice. Median indicated. Data are representative of two independent experiments.(G) *CSF2* expression by leukocyte subsets across different human gut tissue sites (ArrayExpress: [E-MTAB-8007](array-express:E-MTAB-8007){#intref0325}, [E-MTAB-8474](array-express:E-MTAB-8474){#intref0330}), and by colonic leukocyte subsets in ulcerative colitis patients (UC; non-involved UC) and health controls (dataset SCP259) by scRNA-seq.p values were calculated using IPA software (B and D) or the nonparametric Mann-Whitney U test (F). ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001; ^∗∗∗∗^p \< 0.0001. See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

Several leukocyte subsets can produce GM-CSF, including Th17 cells and ILCs ([@bib22]; [@bib49]). To identify the major source of colonic GM-CSF, we profiled cytokine production across ILC and T cell subsets in DSS-treated and control C57BL/6 mice ([Figures 1](#fig1){ref-type="fig"}E and [S1](#mmc1){ref-type="supplementary-material"}F). ILC3s were the major GM-CSF-producing cell type in the colon ([Figure 1](#fig1){ref-type="fig"}F), with lower levels detected in γδ T cells and ILC2s. While the frequency of GM-CSF^+^ cells did not change with DSS administration ([Figure S1](#mmc1){ref-type="supplementary-material"}G), GM-CSF production on a per cell basis was only augmented in ILC3s during intestinal inflammation ([Figure 1](#fig1){ref-type="fig"}F), identifying them as the important dynamic source of GM-CSF during inflammation. Similarly, in human intestinal samples, analysis of scRNA-seq data confirmed ILCs as the major cellular source of GM-CSF in the colon in homeostasis ([Figure 1](#fig1){ref-type="fig"}G), with augmented transcript levels evident in inflamed ulcerative colitis ([Figure 1](#fig1){ref-type="fig"}G).

ILCs and GM-CSF Augment Intestinal Macrophage Activation during Enteropathic Infection and Colitis {#sec2.2}
--------------------------------------------------------------------------------------------------

To investigate the effect of ILC-derived GM-CSF on intestinal MNP function, we depleted ILCs from *Rag1/2*^−/−^ mice, which lack adaptive immunity thereby avoiding the confounding effects of T cell-derived cytokines. Anti-CD90.2 and control antibody-treated mice were challenged with the enteropathic bacterium *Citrobacter rodentium* or dextran sodium sulfate (DSS), a colitogen that induces epithelial barrier breakdown ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B). ILC depletion led to a reduction in disease severity and local inflammation in mice challenged with DSS, as evidenced by lower weight loss, colon weight, and colon shortening ([Figures 2](#fig2){ref-type="fig"}A and [S2](#mmc1){ref-type="supplementary-material"}C), as well as improved survival ([Figure S2](#mmc1){ref-type="supplementary-material"}D). Conversely, in response to *C. rodentium* challenge, ILC-depleted mice exhibited a higher local and systemic bacterial burden at day 7 post-infection ([Figures 2](#fig2){ref-type="fig"}B and 2C). Despite this higher bacterial burden, colon length was also significantly greater in anti-CD90.2 IgG treated mice following *C. rodentium* challenge ([Figure S2](#mmc1){ref-type="supplementary-material"}E), consistent with an attenuated local inflammatory response. Commensurate with a central role for GM-CSF in these clinical phenotypes, neutralization with an anti-GM-CSF antibody improved clinical parameters in DSS-induced colitis to a similar extent to that observed with ILC depletion, including reduced weight loss and increased colon length ([Figure 2](#fig2){ref-type="fig"}D). Next, we profiled immune cell infiltrates; intestinal CX3CR1^+^ macrophages are derived from infiltrating monocytes that progressively lose Ly6C expression and increase MHC-II expression (P1 → P4 subsets) ([@bib64]; [Figure S2](#mmc1){ref-type="supplementary-material"}F). During colitis, Ly6C^lo^ MHC-II^+^ CX3CR1^int^ P3 macrophages are largely derived from newly recruited inflammatory monocytes, while F4/80^hi^ P4 macrophages include a small number of resident macrophages ([@bib1]; [@bib56]; [@bib77]). We observed a reduction in maturing macrophage populations (P2 → P4) following ILC depletion, with little change in monocyte numbers ([Figure 2](#fig2){ref-type="fig"}E). Indeed, we observed a relative increase in the proportion of newly infiltrated monocytes (P1) among CX3CR1^+^ MNPs following DSS challenge ([Figure 2](#fig2){ref-type="fig"}F), suggesting defective monocyte maturation in the absence of ILCs. GM-CSF neutralization led to a similar proportional increase in colonic monocytes ([Figure 2](#fig2){ref-type="fig"}G). ILC depletion also led to a reduction in colonic neutrophil infiltration, with little change in eosinophil number ([Figure S2](#mmc1){ref-type="supplementary-material"}G). CX3CR1^+^ MNPs also differed phenotypically following ILC depletion, with a pronounced reduction in pro-IL-1β expression across MNP subsets ([Figures 2](#fig2){ref-type="fig"}H and [S2](#mmc1){ref-type="supplementary-material"}H), as well as reduced cellular granularity and MHC-II expression ([Figures 2](#fig2){ref-type="fig"}I and [S2](#mmc1){ref-type="supplementary-material"}I), that was phenocopied by GM-CSF neutralization. Importantly, we did not observe GM-CSF expression in CD90.2^+^ non-hematopoietic cells in the colon ([Figure S2](#mmc1){ref-type="supplementary-material"}J).Figure 2ILCs and Innate GM-CSF Augment Intestinal Macrophage Activation during Enteropathic Infection and Colitis(A) Weight change (left) and colon clinical parameters (right) in *Rag2*^−/−^ mice treated with 2% DSS ± isotype (n = 5) or anti-CD90.2 IgG (n = 5) antibodies. Mean ± SEM (weight change) and medians (colon parameters) indicated.(B and C) *C. rodentium* colony-forming units (CFUs) in caecum (B) and liver (C) from isotype (n = 8) or anti-CD90.2 IgG treated (n = 9) *Rag2*^*−/−*^ mice at 7 days post-infection (dpi). Medians indicated in (B).(D) Clinical parameters in *Rag2*^−/−^ mice treated as in (A) or anti-GM-CSF IgG antibodies for 6 days. Mean ± SEM (weight change) and medians (colon parameters) indicated. n = 5 per group.(E) Relative colonic CX3CR1^+^ MNP counts in mice treated as in (A). Data normalized to isotype. Medians indicated. n = 8--9 per group.(F and G) Proportion of P1 monocytes of total MNPs, normalized to isotype IgG, from mice treated in (A)--(F) or in (D)--(G). Median indicated. n = 5 per group.(H) Pro-IL-1β expression by colonic MNP subsets in mice treated as in (A) (top row, n = 8--9 per group) or in (D) (bottom row, n = 5 per group).(I) MHC-II expression in P3/P4 colonic MNPs in mice treated as in (A) or as in (D). Medians indicated. n = 5--9 per group.(J) IL-22 and GM-CSF production by CD90.2^hi^ SCA-1^+^ ILCs in *Rag2*^−/−^ mice treated as in (D). Medians indicated. n = 5 per group.(K) Colon tissue qPCR of IL-22-dependent epithelium genes in mice treated as in (D).n = 4--5 per group. Data are representative of three or more independent experiments, with single experiments (A--E, G, J, and K) or two pooled independent experiments (F, H, and I) shown. p values were calculated using a two-way ANOVA with Sidak's multiple comparisons test (A) (for weight loss), the nonparametric Mann-Whitney U test (A) (for colon parameters), in (B) and (D) (for colon parameters), and in (F)--(K), Chi-square test (C), two-way ANOVA with Tukey's multiple comparisons test (D) (weight loss), and multiple t tests with Holm-Sidak correction (E). ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001; ^∗∗∗∗^p \< 0.0001. See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

IL-1β is a potent activator of ILC3 cytokine production *in vitro* ([Figure S2](#mmc1){ref-type="supplementary-material"}K). Given the profound effect of ILC depletion or GM-CSF neutralization on macrophage activation and the production of IL-1β *in vivo*, we hypothesized that the downstream type 17 response induced by IL-1β may be regulated by GM-CSF through ILC3-MNP crosstalk. *In vitro* ILC3 secretion of IL-22 during co-culture with macrophages was attenuated by GM-CSF neutralization ([Figure S2](#mmc1){ref-type="supplementary-material"}L), despite an absence of GM-CSF receptor expression on intestinal ILC3s ([Figure S2](#mmc1){ref-type="supplementary-material"}M), suggesting that ILC3-derived GM-CSF ultimately amplifies ILC activation via its effects on macrophage cytokine production. *In vivo*, neutralization of GM-CSF in *Rag2*^−/−^ mice subjected to DSS-induced colitis reduced IL-22 and GM-CSF production by CD90.2^hi^ SCA1^+^ ILC3s ([Figure 2](#fig2){ref-type="fig"}J). Furthermore, expression of IL-22-dependent genes produced by the intestinal epithelium were attenuated by GM-CSF neutralization, including RegIIIγ ([Figure 2](#fig2){ref-type="fig"}K) demonstrating that optimal ILC3 activation is dependent on GM-CSF-mediated MNP priming via a positive feedback loop.

GM-CSF Drives Inflammatory Macrophage Function and Type 17 Immunity *In Vivo* {#sec2.3}
-----------------------------------------------------------------------------

Although GM-CSF neutralization phenocopied the clinical and immunological features of ILC depletion *in vivo*, we sought to more closely interrogate whether the principal impact of ILCs on intestinal macrophage function was due to GM-CSF secretion. To address this question, we performed RNA sequencing (RNA-seq) on sorted colonic Ly6C^lo^ MHC-II^hi^ macrophages from ILC-depleted mice following induction of DSS colitis. We observed widespread changes in gene expression in colonic macrophages in the absence of ILCs ([Figure S3](#mmc1){ref-type="supplementary-material"}A), including downregulation of several important gene networks, most notably IL-12/23-associated innate immune activation ([Figure S3](#mmc1){ref-type="supplementary-material"}B). In line with the observed reduction in colonic macrophage IL-1β production, gene set enrichment analysis (GSEA) also demonstrated a significant reduction in an inflammasome-associated gene set in intestinal macrophages in the absence of ILCs, including *Nlrp3* and *Il1b* ([Figure S3](#mmc1){ref-type="supplementary-material"}C).

IPA of upstream regulators predicted to be attenuated following ILC depletion identified GM-CSF as a central cytokine regulator that was deficient in the absence of ILCs ([Figure 3](#fig3){ref-type="fig"}A). Consistent with this, transcription factor (TF) analysis demonstrated a reduction in *Bhlhe40* (recently shown to be a GM-CSF-dependent TF in alveolar macrophages) ([@bib23]) in intestinal macrophages isolated from ILC-depleted mice ([Figure 3](#fig3){ref-type="fig"}B). Furthermore, in the absence of ILCs, there was a significant reduction in other components of the GM-CSF signaling pathway, including *Csf2rb* and *Csf2rb2* and the intracellular signaling molecule *Jak2* ([Figure S3](#mmc1){ref-type="supplementary-material"}D). Indeed, comparison of the transcriptome of macrophages cultured in the presence or absence of GM-CSF for 24 h *in vitro* to that of colonic macrophages isolated following ILC depletion demonstrated that genes that were highly induced by GM-CSF were significantly reduced in colonic macrophages following ILC depletion, with a corresponding increase in genes suppressed by GM-CSF ([Figure 3](#fig3){ref-type="fig"}C). Therefore, in the absence of ILCs, intestinal macrophages exhibit a pronounced defect in GM-CSF-associated gene expression consistent with the conclusion that ILCs represent an important source of GM-CSF *in vivo* that drives an inflammatory macrophage phenotype.Figure 3GM-CSF Drives Inflammatory Macrophage Function and Type 17 Immunity *In Vivo*(A) GM-CSF-associated upstream regulatory network downregulated by anti-CD90.2 IgG treatment, derived by IPA, in colonic Ly6C^lo^ MHC-II^+^ macrophages from *Rag2*^−/−^ mice treated with 2% DSS ± isotype or anti-CD90.2 IgG. n = 6 per group.(B) RNA-seq volcano plot of transcriptional regulators (GO:0140110) from macrophages in (A).(C) GSEA of the GM-CSF signatures (top 200 GM-CSF-induced (left) or GM-CSF-suppressed (right) genes in BMDMs) in colonic Ly6C^lo^ MHC-II^+^ macrophages from (A). GM-CSF signatures derived from ArrayExpress: [E-MTAB-792](array-express:E-MTAB-792){#intref0335}.(D) Weight change (left) and cecal CFU at 10 dpi (right) in 100% *Csf2rb*^+/+^ and 100% *Csf2b*^−/−^ bone marrow chimeras infected with *C. rodentium*. Mean ± SEM indicated. n = 5 per group.(E) Proportion of P1 monocytes of total CX3CR1^+^ CD11b^+^ MNPs in bone marrow chimeras, normalized to *Csf2rb*^+/+^ mice.(F and G) Waterfall subset frequency (F) and pro-IL-1β expression (G) of paired *Csf2rb*^+/+^ and *Csf2rb*^−/−^ colonic MNP subsets in 80:20 bone marrow chimeric mice at 7 dpi with *C. rodentium*.(H) MHC-II expression and side scatter of Ly6C^lo^ MHC-II^+^ macrophages in (F).(I and J) Type 17 cytokine production by CD4^+^ T cells (I) and ILCs (J) in 100% *Csf2rb*^+/+^ or 100% *Csf2rb*^−/−^ bone marrow chimeric mice at 10 dpi with *C. rodentium*.Mean ± SEM indicated. n = 4--5 per group. Data are representative of two independent experiments. p values were calculated using IPA software (A), standard DESeq 2 method with multiple comparisons correction using the Benjamini-Hochberg procedure (B), two-way ANOVA with Sidak's multiple comparisons test (D) (weight loss), Student's t test (D \[CFU analysis\], I, and J), Mann-Whitney U test (E), and a paired t test (F--H). ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001; ^∗∗∗∗^p \< 0.0001. See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

While a useful and commonly used model to study ILC function in the absence of cofounding T cell effects, *Rag1/2*^−/−^ mice are known to have a hyperactivated ILC compartment due to the absence of regulatory T cells ([@bib15]). Therefore, we sought to determine the importance of GM-CSF in driving an inflammatory macrophage phenotype in immune-replete animals by generating bone marrow chimeras with *Csf2rb*^−/−^ bone marrow ([Figure S3](#mmc1){ref-type="supplementary-material"}E). Despite similar immune reconstitution ([Figures S3](#mmc1){ref-type="supplementary-material"}F and S3G), mice receiving 100% *Csf2rb*^−/−^ bone marrow were more susceptible to challenge with *C. rodentium* ([Figures 3](#fig3){ref-type="fig"}D and [S3](#mmc1){ref-type="supplementary-material"}H) compared to mice receiving 100% wild-type (WT) bone marrow. As with GM-CSF neutralization, absence of GM-CSF receptor signaling caused an accumulation of immature monocytes ([Figure 3](#fig3){ref-type="fig"}E) and a reduction in pro-IL-1β expression by intestinal MNPs ([Figure S3](#mmc1){ref-type="supplementary-material"}I). To determine if the effect of GM-CSF in promoting intestinal macrophage function was cell-intrinsic, we generated mixed *Csf2rb*^−/−^:*Csf2rb*^+/+^ bone marrow chimeras ([Figure S3](#mmc1){ref-type="supplementary-material"}E). Relative to CD45.1^+^ WT cells, *Csf2rb*^−/−^ CX3CR1^+^ MNP waterfall subsets were impaired in their maturation from monocytes to Ly6C^lo^MHC-II^hi^ macrophages ([Figure 3](#fig3){ref-type="fig"}F) and in their ability to produce pro-IL-1β ([Figure 3](#fig3){ref-type="fig"}G), with macrophages showing reduced MHC-II expression and granularity ([Figure 3](#fig3){ref-type="fig"}H).

In the absence of macrophage responsiveness to GM-CSF, there was also an attenuation of T cell-derived IL-17A and IL-22 ([Figure 3](#fig3){ref-type="fig"}I). Furthermore, IL-22 production, but not IL-17A, by CD4^−^ CD3^−^ CD90.2^hi^ ILC3s was also impaired in the absence of GM-CSF receptor signaling ([Figures 3](#fig3){ref-type="fig"}J and [S3](#mmc1){ref-type="supplementary-material"}J), with no difference in colonic B cells ([Figure S3](#mmc1){ref-type="supplementary-material"}K).

ILCs and GM-CSF Promote M1 and Suppress M2 Colonic Macrophage Polarization {#sec2.4}
--------------------------------------------------------------------------

Hallmarks pathway analysis of our colonic macrophage RNA-seq dataset demonstrated a reduction in a number of canonical inflammatory pathways and in glycolysis genes following ILC depletion, consistent with a pro-inflammatory role for GM-CSF ([Figure 4](#fig4){ref-type="fig"}A). However, we also noted an increase in pathways associated with tissue repair and regeneration, including epithelial-mesenchymal transition, myogenesis, and angiogenesis ([Figure 4](#fig4){ref-type="fig"}A). Such polarization of macrophage function is reminiscent of pro-inflammatory M1 and anti-inflammatory M2 macrophage phenotypes ([@bib41]). We therefore hypothesized that during intestinal infection and inflammation, the presence of ILCs promotes an M1 phenotype in tissue macrophages while suppressing a wound healing M2-like response. Consistent with this, we observed increased expression of genes associated with M2 macrophage activation, such as *Retnla*, *Pparg*, and *Tgfbr2*, in colonic macrophages of ILC-depleted mice ([Figure 4](#fig4){ref-type="fig"}B). Furthermore, alignment of our sorted colonic macrophage dataset with the transcriptional profiles of a spectrum of macrophage activation states ([@bib75]) demonstrated a significant reduction in the M1 LPS-stimulated macrophage signature and an increase in the IL-4 M2 signature following ILC depletion ([Figure 4](#fig4){ref-type="fig"}C). Together, these data suggest that ILCs regulate intestinal macrophage polarization, controlling the balance of pro-inflammatory anti-microbial and pro-repair phenotypes that ultimately shapes the course of inflammation.Figure 4ILCs and GM-CSF Regulate Intestinal Macrophage Polarization(A) GSEA of top Hallmarks pathways in colonic Ly6C^lo^ MHC-II^+^ MNPs from *Rag2*^−/−^ mice treated with anti-CD90.2 IgG or isotype control and 2% DSS.(B) Expression of M2 alternative activation genes in colonic MNPs from (A). Medians indicated.(C) GSEA of top 100 DEGs from human monocyte-derived macrophages (MDMs) treated with various stimuli in colonic MNPs from (A). Data derived from GEO: [GSE47189](ncbi-geo:GSE47189){#intref0340}.(D) Expression of M1 versus M2 genes between flow-sorted intestinal CD45.1^+^*Csf2rb*^+/+^ and CD45.2^+^*Csf2rb*^−/−^ Ly6C^lo^ MHC-II^+^ MNPs in 80:20 chimeric mice. Data were derived from pooled Ly6C^lo^ MHC-II^+^ macrophages from 5 mice.(E) Correlation between single sample GSEA scores of ILC (left) or *CSF2* levels (right) with M1 signatures in ulcerative colitis (healthy control \[HC\] n = 11, non-inflamed UC n = 23, active UC n = 74) and ileal Crohn's disease biopsies (HC n = 35, ileal CD n = 210). Data derived from GEO: [GSE59071](ncbi-geo:GSE59071){#intref0345} and GEO: [GSE93624](ncbi-geo:GSE93624){#intref0350}. p values were calculated using the standard DESeq 2 method with multiple comparisons correction using the BH procedure (B), and Spearman's rank correlation with multiple testing correction (E). ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001; ^∗∗∗∗^p \< 0.0001.See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

To determine whether GM-CSF signaling was required for the polarization of intestinal macrophages *in vivo*, we flow-sorted WT and *Csf2rb*^−/−^ intestinal MHC-II^+^ CD64^+^ macrophages from mixed bone marrow chimeric mice following challenge with *C. rodentium* and performed qPCR. In addition to pro-IL-1β and MHC-II ([Figure 3](#fig3){ref-type="fig"}), *Csf2rb*^−/−^ macrophages had reduced expression of *Il23a*, *Nos2*, and *Slc2a1*, and an increase in *Il10* and *Tgfbr2* expression ([Figure 4](#fig4){ref-type="fig"}D), consistent with a reduction in M1 transcriptional programs and an increase in M2 polarization in the absence of GM-CSF *in vivo*.

ILC3s have been implicated in IBD pathogenesis, with increased numbers of ILC3s observed in inflamed intestine in Crohn's disease (CD) in particular ([@bib5]; [@bib18]). To test whether ILC might influence differing macrophage polarization in human IBD, we analyzed mucosal biopsies from patients with ulcerative colitis (UC) and ileal CD, as well as healthy controls. Using cell signatures derived from a recent intestinal scRNA-seq dataset ([@bib60]), we performed single sample gene set enrichment analysis and demonstrated a significant positive correlation between ILC and M1 macrophage signatures in disease biopsies ([Figure 4](#fig4){ref-type="fig"}E). Although correlation does not prove causation, these data mirror our findings in the murine intestine, and are consistent with a role for ILCs in controlling macrophage polarization during human intestinal inflammation. Furthermore, this association was substantially stronger than that of T cell signatures with the M1 macrophage signature ([Figure S4](#mmc1){ref-type="supplementary-material"}A). *CSF2* transcripts also showed a strong positive correlation with M1 macrophage enrichment scores in colonic UC and ileal CD ([Figure 4](#fig4){ref-type="fig"}E), higher than other ILC-related cytokines ([Figure S4](#mmc1){ref-type="supplementary-material"}B), supporting the conclusion that ILC3-derived GM-CSF shapes intestinal macrophage polarization in human disease.

ILC3-Derived GM-CSF Drives Macrophage Inflammatory Phenotype {#sec2.5}
------------------------------------------------------------

To more directly assess the contribution of ILCs to macrophage polarization *in vivo*, we flow-sorted intestinal RORγt^+^ ILC3s, the major source of dynamic GM-CSF production in colitis ([Figure 1](#fig1){ref-type="fig"}F) and co-cultured them with bone marrow-derived macrophages. The presence of ILC3s ([Figure 5](#fig5){ref-type="fig"}A) or ILC3-conditioned media ([Figure S5](#mmc1){ref-type="supplementary-material"}A) enhanced macrophage IL-1β and MHC-II expression, and suppressed IL-10, effects that were inhibited by the addition of a GM-CSF-neutralizing antibody. Similarly, ILC3-conditioned media increased *Tnfsf15* (encoding TL1A), *Il6*, and *Nos2* expression in macrophages, with the increase in *Tnfsf15* and *Il6* being GM-CSF-dependent ([Figure S5](#mmc1){ref-type="supplementary-material"}A). *In vitro*, GM-CSF treatment altered macrophage morphology, increasing surface projections and reducing sphericity ([Figures 5](#fig5){ref-type="fig"}B, 5C, and [S5](#mmc1){ref-type="supplementary-material"}B; [Videos S1](#mmc2){ref-type="supplementary-material"} and [S2](#mmc3){ref-type="supplementary-material"}). Time-lapse imaging demonstrated enhanced macrophage motility and seeks behavior following GM-CSF treatment ([Figures 5](#fig5){ref-type="fig"}C and [S5](#mmc1){ref-type="supplementary-material"}B). We observed GM-CSF-dependent increase in phagocytosis of fecal commensals (labeling demonstrated in [Figure S5](#mmc1){ref-type="supplementary-material"}C) in macrophages co-cultured with ILC3s ([Figure 5](#fig5){ref-type="fig"}D), consistent with the conclusion that the changes in dynamic behavior increase cellular "search area" and bacterial uptake. Conversely, *in vivo*, macrophages from ILC-depleted colons exhibited an impaired ability to phagocytose commensals, an effect specific to macrophages, with neutrophil phagocytosis unaffected ([Figure 5](#fig5){ref-type="fig"}E). Furthermore, colonic MNPs from ILC-depleted mice demonstrated reduced expression of several pattern recognition receptor (PRR)-mediated signaling pathways ([Figure S5](#mmc1){ref-type="supplementary-material"}D). In summary, these data suggest that ILC3-derived GM-CSF augments the inflammatory and microbicidal activity of intestinal macrophages, potentially contributing to the altered systemic spread of bacteria observed with ILC depletion or GM-CSF neutralization.Figure 5ILC3-Derived GM-CSF Regulates MNP Microbicidal Activity and Metabolism(A) Cytokine and MHC-II expression in BMDMs cultured with ILC3s ± isotype or anti-GM-CSF IgG for 16 h. Mean ± SEM indicated from triplicates.(B and C) Morphology and motility analysis of BMDMs after 48 h culture ± control or GM-CSF-supplemented media. Medians are indicated. Scale bar, 10 μm.(D and E) Phagocytosis of fluorescent commensal microbes by BMDMs co-cultured as in (A) for 72 h (D) or by colonic MNP subsets and neutrophils from mice treated with isotype or anti-CD90.2 IgG at day 6 post 2% DSS administration (E). Mean ± SEM indicated from triplicates.(F) *Slc2a1* expression in BMDMs co-cultured as in (A). Mean ± SEM indicated from triplicates.(G) ECAR and OCR for BMDMs primed with ILC3-conditioned media compared to control media for 16 h. Mean ± SEM indicated from 6 measurements.(H) Basal metabolic profile of BMDMs in (G). Mean ± SEM indicated.(I) Analysis of features of glycolytic metabolism in BMDMs cultured as in (G) ± anti-GM-CSF IgG. Mean ± SEM indicated from 6 measurements.(J) IL-1β production by BMDMs primed with GM-CSF or control media for 16h before stimulation with fecal commensals (FC) and 2DG for 6 h.Mean ± SEM indicated from triplicates. Data are representative of two (D, E, and G--J) or three (A, B, and F) independent experiments. p values were calculated using a one-way ANOVA with Tukey's multiple comparisons test (A, D, and F), Mann-Whitney U test (C), Student's t test (E), multiple t tests with Holm-Sidak's multiple comparisons test (G), and two-way ANOVA with Tukey's multiple comparisons test (I and J). ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001; ^∗∗∗∗^p \< 0.0001. See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

Video S1Control Macrophage Motility Analysis, Related to Figure 5 Time-lapse imaging of control BMDMs in a 3-dimensional collagen gel. Data representative of two independent experiments.

Video S2GM-CSF Macrophage Motility Analysis, Related to Figure 5 Time-lapse imaging of GM-CSF-primed BMDMs in a 3-dimensional collagen gel. Data representative of two independent experiments.

Given the widespread changes in colonic macrophages, we hypothesized that ILC3s may regulate the metabolic profile of macrophages to support enhanced microbicidal and inflammatory activity. There was a significant reduction in macrophage expression of *Glycolysis* pathway genes in the absence of ILCs ([Figure S5](#mmc1){ref-type="supplementary-material"}E), including *Hk2* and *Ldha* ([Figure S5](#mmc1){ref-type="supplementary-material"}F). Co-culture of macrophages with ILC3s or ILC3-conditioned media was sufficient to induce GM-CSF-dependent expression of glycolytic genes, including *Slc2a1* and *Hk2* ([Figures 5](#fig5){ref-type="fig"}F and [S5](#mmc1){ref-type="supplementary-material"}G), and to alter the metabolic phenotype of macrophages ([Figure 5](#fig5){ref-type="fig"}G). ILC3 co-culture increased both the extracellular acidification rate (ECAR) and the oxygen consumption rate (OCR) ([Figure 5](#fig5){ref-type="fig"}G), consistent with an "energetic" phenotype ([@bib42]; [Figure 5](#fig5){ref-type="fig"}H). ILC3s increased the glycolytic reserve and capacity of macrophages, in a GM-CSF-dependent manner ([Figures 5](#fig5){ref-type="fig"}I and [S5](#mmc1){ref-type="supplementary-material"}H). This metabolic reprogramming was essential for enhanced macrophage activity, as evidenced by the reduction in GM-CSF-induced IL-1β production in the presence of 2-deoxy-D-glucose (2DG), an inhibitor of glycolysis ([Figure 5](#fig5){ref-type="fig"}J).

ILC3s Suppress a Pro-repair Macrophage Phenotype {#sec2.6}
------------------------------------------------

In addition to the reduction in inflammatory gene networks in macrophages obtained from ILC-depleted mice, we also noted an induction of tissue reparative transcriptional programs ([Figure 4](#fig4){ref-type="fig"}A), suggesting that ILC3-derived GM-CSF might actively suppress a pro-repair, wound-healing phenotype in macrophages. Indeed, many of the genes within the epithelial-mesenchymal transition gene set enriched in macrophages isolated from ILC-depleted colons were those required for collagen formation or interaction ([Figures 6](#fig6){ref-type="fig"}A and [S6](#mmc1){ref-type="supplementary-material"}A), suggesting that intestinal macrophages may directly contribute to the restoration of the extracellular matrix (ECM) following epithelial barrier breach. Among collagen gene transcripts, *Col4a1* was the most upregulated in macrophages following ILC depletion ([Figure 6](#fig6){ref-type="fig"}B), and its expression in BMDM was decreased by the addition of GM-CSF or ILC3 culture supernatants in a GM-CSF-dependent manner ([Figure 6](#fig6){ref-type="fig"}C). Notably, collagen synthesis has been demonstrated in macrophages adopting a myofibroblast-like phenotype during tissue and wound repair ([@bib38]; [@bib59]).Figure 6ILCs Suppress a Pro-repair Macrophage Phenotype(A) GSEA of hallmarks *epithelial-mesenchymal transition* pathway in colonic Ly6C^lo^ MHC-II^+^ MNPs from *Rag2*^−/−^ mice treated with 2% DSS ± isotype or anti-CD90.2 IgG for 6 days, with percentage of leading-edge genes involved in collagen formation/interaction shown. n = 6 per group.(B) Expression of collagen subunits in colonic MNPs in (A).(C) *Col4a1* expression by BMDMs primed with GM-CSF or control media (left) or with ILC3-conditioned media ± anti-GM-CSF IgG for 16 h (right). Mean ± SEM indicated from triplicates.(D and E) RNA-seq GSEA of hallmarks pathways (D) and murine colonic stromal cell signatures (E), derived from murine DSS scRNA-seq dataset GEO: [GSE114374](ncbi-geo:GSE114374){#intref0355}, in whole colonic tissue of mice treated as in (A). n = 5 per group.(F) Growth factor expression in colonic MNPs as in (A). Red dots = p value \<0.05.(G) *Pdgfb* expression in BMDMs treated as in (C). Mean ± SEM indicated from triplicates.(H and I) Scratch wound assay of murine fibroblasts cultured in conditioned medium from GM-CSF-primed or control BMDMs, or treated with recombinant murine PDGF-BB or control. Mean ± SEM indicated from 5 measurements.(J) GSEA of the top 200 upregulated genes in colonic Ly6C^lo^ MHC-II^+^ following anti-CD90.2 IgG administration in mucosal biopsies of complicated (n = 27) versus non-complicated (n = 183) ileal Crohn's disease, derived from GEO: [GSE93624](ncbi-geo:GSE93624){#intref0360}.Data are representative of two (H and I) or three (C and G) independent experiments. p values were calculated using standard DESeq 2 method (RNA-seq) or limma (microarray) with multiple comparisons correction using the BH correction (B and F), one-way ANOVA with Tukey's multiple comparisons test (C and G), and multiple t tests with Holm-Sidak's multiple comparisons test (I). ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001; ^∗∗∗∗^p \< 0.0001. See also [Figure S6](#mmc1){ref-type="supplementary-material"}.

To interrogate if there was evidence for more avid tissue repair beyond macrophages in the absence of ILCs, we assessed transcriptional changes in whole colon samples in DSS colitis ([Figure S6](#mmc1){ref-type="supplementary-material"}B). This confirmed an increase in tissue reparative pathways, including myogenesis and epithelial-mesenchymal transition genes in the absence of ILC ([Figure 6](#fig6){ref-type="fig"}D). The intestinal mesenchyme is comprised of a variety of cell types that form the intestinal ECM and connective tissue between the epithelium and muscularis mucosae ([@bib51]). To determine if there was an increase in any specific mesenchymal cell type in the context of ILC depletion, we curated single cell signatures of all major murine colonic mesenchymal cell types ([@bib29]) and assessed the relative enrichment of these cell type signatures in our colonic RNA-seq dataset. This demonstrated a significant enrichment of myofibroblast genes in ILC-depleted colons ([Figures 6](#fig6){ref-type="fig"}E and [S6](#mmc1){ref-type="supplementary-material"}C), including *Acta2* that encodes α-SMA ([Figure S6](#mmc1){ref-type="supplementary-material"}D). Myofibroblasts principally arise from fibroblasts and play an important role in wound repair ([@bib65]). In addition, fibroblasts and myofibroblasts may also regulate intestinal stem cell activity via the production of Wnt signals ([@bib19]; [@bib32]; [@bib46]). Notably, we observed an enrichment of Hedgehog signaling and WNT beta catenin signaling pathway genes in ILC-depleted colons ([Figure 6](#fig6){ref-type="fig"}D), both of which regulate stem cell fate in intestinal crypts ([@bib16]; [@bib69]).

Macrophages are well known to play a critical role in wound healing by secreting molecules that can activate fibroblasts and myofibroblasts ([@bib74]), for example, PDGF ([@bib57]). We therefore hypothesized that ILC3-derived GM-CSF might not only inhibit a fibroblast/myofibroblast-like phenotype in macrophages, but also their ability to stimulate mesenchymal cells. In keeping with this, colonic macrophages from ILC-depleted mice showed an increase in *Col6a1*, *Col6a2*, and *Col6a3* transcripts ([Figure 6](#fig6){ref-type="fig"}B) that together form trimers that make up collagen type VI, previously shown to promote myofibroblast activation in the context of lung fibrosis ([@bib67]). We also found a marked increase in several growth factor transcripts in colonic macrophages ([Figure 6](#fig6){ref-type="fig"}F) and colonic levels of *Pdgfb* were globally elevated in the absence of ILCs ([Figure S6](#mmc1){ref-type="supplementary-material"}E). PDGF-BB has potent pro-wound healing effects, and indeed is licensed for use clinically in the treatment of wounds ([@bib3]; [@bib40]). *In vitro*, macrophage expression of *Pdgfb* was directly suppressed by GM-CSF and by ILC3-conditioned media in a GM-CSF-dependent manner ([Figures 6](#fig6){ref-type="fig"}G and [S6](#mmc1){ref-type="supplementary-material"}F). Addition of GM-CSF-treated macrophage conditioned media to fibroblast cultures inhibited the restoration of monolayer integrity following physical damage ([Figure 6](#fig6){ref-type="fig"}H, I), while addition of exogenous PDGF-BB promoted this wound-healing response ([Figure 6](#fig6){ref-type="fig"}I).

Tissue reparative programs may be helpful to repair barrier breach but if dysregulated may result in fibrosis and intestinal stricturing ([@bib47]). This represents a serious complication of IBD, and is particularly associated with ileal CD ([@bib48]). We therefore hypothesized that the effect of ILC3-derived GM-CSF on macrophage polarization may be beneficial in reducing progression to intestinal fibrosis. To test this, we examined the transcriptional profile of biopsies from patients with "complicated" CD, comprising those with stricturing or penetrating disease during a 3-year follow-up period post-biopsy ([@bib36]). We found that the *epithelial-mesenchymal transition* pathway was the most upregulated in these complicated biopsies compared with "non-complicated" biopsies ([Figure S6](#mmc1){ref-type="supplementary-material"}G). Furthermore, genes upregulated in ILC-depleted macrophages were significantly enriched in CD biopsies obtained from patients with complicated disease ([Figure 6](#fig6){ref-type="fig"}J), relative to uncomplicated disease biopsies. This suggests that the magnitude of GM-CSF signaling in macrophages is an important determinant of progression to a stricturing clinical phenotype and is ultimately controlled by ILC3s.

Discussion {#sec3}
==========

GM-CSF has previously been shown to be important for regulating a variety of aspects of intestinal inflammation via its effects on different cell types, including pro-inflammatory and regulatory effects ([@bib20], [@bib21]; [@bib39]; [@bib43]; [@bib61]). Here, we have demonstrated that it plays a critical role in calibrating the phenotype of intestinal macrophages, promoting pro-inflammatory, anti-microbial M1 transcriptional programs while actively suppressing a pro-tissue repair phenotype in the context of ongoing inflammation. Remarkably, depletion of ILCs or neutralization of GM-CSF in the context of enteropathic infection or barrier breach-induced inflammation resulted in enhanced expression of collagen subunits by macrophages, as well as production of fibroblast-stimulating growth factors, including PDGF-BB. Macrophage production of collagen has been previously described in human macrophages *in vitro* and in atherosclerotic plaques ([@bib53]; [@bib71]), in mouse models of kidney ([@bib38]) and lung injury ([@bib67]), and in skin wounds ([@bib59]), consistent with a transition to a fibroblast/myofibroblast phenotype. Indeed, in the latter study, fate-mapping suggested that two-thirds of granulation tissue fibroblasts in the wound were of myeloid origin ([@bib59]). Recently, collagen-producing macrophages were shown to directly enhance scar formation *in vivo* in murine and zebrafish models of cardiac fibrosis, in particular through expression of *Col4a1* ([@bib58]). Our study reveals that the tissue milieu during infection or barrier breach provides signals that promote this reparative phenotype in intestinal macrophages, but this is kept in check by local GM-CSF. An excessive wound healing response may result in tissue fibrosis, a well-described complication in IBD. Indeed, strictures represent a major cause of chronic morbidity in CD. Our data raises the possibility that the magnitude of GM-CSF signaling in macrophages is an important determinant of progression to this serious clinical phenotype. In keeping with this, CD patients with detectable GM-CSF autoantibodies have increased frequency of luminal narrowing and strictures ([@bib14]; [@bib27]). Furthermore, impaired GM-CSF bioactivity has been associated with accelerated surgical recurrence in patients with ileal CD ([@bib17]) and a frameshift mutation in *CSF2RB* that increases the risk for CD results in reduced monocyte responses to GM-CSF ([@bib8]). However, the effects of GM-CSF in balancing macrophage polarization, where extremes at either end may result in different types of pathology, inflammation versus stricturing, may explain some of the conflicting data observed with regards to the role of GM-CSF in IBD in humans; recombinant GM-CSF has been used treat CD patients with moderate to severe disease activity and had a high rate of clinical response and remission ([@bib12]; [@bib30]) leading to its application to a randomized phase II clinical trial that confirmed superiority to placebo in obtaining a corticosteroid-free clinical remission ([@bib68]). However, a larger randomized trial found that it was no more effective than placebo for induction of clinical remission or improvement in active CD ([@bib50]). Our work would suggest that recombinant GM-CSF may be more useful in a subset of patients with a stricturing phenotype.

Given the increasing appreciation of macrophage heterogeneity in the intestine ([@bib11]; [@bib56]; [@bib77]), further work is required to dissect the role of GM-CSF across macrophage subsets, for example long-lived CD4^+^ Tim-4^+^ macrophages and those resident in the muscularis layer, in both health and disease.

In summary, our data reveal that GM-CSF plays a critical role in shaping macrophage metabolism, polarization and function, and that this is largely derived from ILC3s. This ILC3-macrophage crosstalk calibrates macrophage phenotype, balancing pro-inflammatory and pro-wound healing functionality to determine the strength of anti-bacterial responses during infection and inflammation, and susceptibility to fibrosis during tissue repair, with potential therapeutic implications for IBD.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Anti-mouse B220 antibody (RA3-6B2)Thermo Fisher ScientificCat\#25-0452-82; RRID:[AB_469627](nif-antibody:AB_469627){#intref0010}Anti-mouse CD3 antibody (145-2C11)Thermo Fisher ScientificCat\#11-0031-82; RRID:[AB_464882](nif-antibody:AB_464882){#intref0015}Anti-mouse CD4 antibody (GK1.5)Thermo Fisher ScientificCat\#47-0041-82; RRID:[AB_11218896](nif-antibody:AB_11218896){#intref0020}Anti-mouse CD11b antibody (M1/70)Thermo Fisher ScientificCat\#11-0112-82; RRID:[AB_464935](nif-antibody:AB_464935){#intref0025}Anti-mouse CD11c antibody (N418)Thermo Fisher ScientificCat\#25-0114-82; RRID:[AB_469590](nif-antibody:AB_469590){#intref0030}Anti-mouse CD19 antibody (6D5)BiolegendCat\#115543; RRID:[AB_11218994](nif-antibody:AB_11218994){#intref0035}Anti-mouse CD45.1 antibody (A20)Thermo Fisher ScientificCat\#A15415; RRID:[AB_2534428](nif-antibody:AB_2534428){#intref0040}Anti-mouse CD45.2 antibody (104)Thermo Fisher ScientificCat\#A14736; RRID:[AB_2534252](nif-antibody:AB_2534252){#intref0045}Anti-mouse CD90.2 antibody (30-H12)Thermo Fisher ScientificCat\#46-0903-82; RRID:[AB_10670882](nif-antibody:AB_10670882){#intref0050}Anti-mouse CD117 antibody (ACK2)Thermo Fisher ScientificCat\#12-1172-81; RRID\_[AB_465815](nif-antibody:AB_465815){#intref0055}Anti-mouse CD127 antibody (A7R34)BiolegendCat\#135014; RRID:[AB_1937265](nif-antibody:AB_1937265){#intref0060}Anti-mouse CX3CR1 antibody (SA011F11)BiolegendCat\#149005; RRID:[AB_2564314](nif-antibody:AB_2564314){#intref0065}Anti-mouse F4/80 antibody (BM8)Thermo Fisher ScientificCat\#11-4801-82; RRID:[AB_2637191](nif-antibody:AB_2637191){#intref0070}Anti-mouse GATA3 antibody (TWAJ)Thermo Fisher ScientificCat\#50-8899-42; RRID:[AB_10596663](nif-antibody:AB_10596663){#intref0075}Anti-mouse GM-CSF antibody (MP1-22E9)BD biosciencesCat\#554406; RRID:[AB_395371](nif-antibody:AB_395371){#intref0080}Anti-mouse IL-17A antibody (TC11-18H10.1)BiolegendCat\#506903; RRID:[AB_315463](nif-antibody:AB_315463){#intref0085}Anti-mouse IL-22 antibody (IL22JOP)Thermo Fisher ScientificCat\#17-7222-82; RRID:[AB_10597583](nif-antibody:AB_10597583){#intref0090}Anti-mouse Ly6C antibody (HK1.4)Thermo Fisher ScientificCat\#45-5932-82; RRID:[AB_2723343](nif-antibody:AB_2723343){#intref0095}Anti-mouse Ly6C/G antibody (RB6-8C5)Thermo Fisher ScientificCat\#47-5931-82; RRID:[AB_1518804](nif-antibody:AB_1518804){#intref0100}Anti-mouse MHC-II (I-A/I-E) antibody (M5/114.15.2)Thermo Fisher ScientificCat\#62-5321-82; RRID:[AB_2688070](nif-antibody:AB_2688070){#intref0105}Anti-mouse pro-IL-1β antibody (NJTEN3)Thermo Fisher ScientificCat\#17-7114-80; RRID:[AB_10670739](nif-antibody:AB_10670739){#intref0110}Anti-mouse RORγt antibody (Q31-378)BD biosciencesCat\#564723; RRID:[AB_2738916](nif-antibody:AB_2738916){#intref0115}Anti-mouse TCR beta antibody (H57-597)Thermo Fisher ScientificCat\#48-5961-82; RRID:[AB_11039532](nif-antibody:AB_11039532){#intref0120}Anti-mouse TCR gamma/delta antibody (GL3)BiolegendCat\#118101; RRID:[AB_313826](nif-antibody:AB_313826){#intref0125}InVivoMab anti-mouse CD90.2 antibody (30H12)BioXCellCat\#BE0066; RRID:[AB_1107682](nif-antibody:AB_1107682){#intref0130}InVivoMab anti-mouse GM-CSF antibody (MP1-22E9)BioXCellCat\#BE0259; RRID:[AB_2687738](nif-antibody:AB_2687738){#intref0135}InVivoMab anti-keyhole limpet hemocyanin antibody (LTF-2)BioXCellCat\#BE0090; RRID:[AB_1107780](nif-antibody:AB_1107780){#intref0140}**Bacterial and Virus Strains***Citrobacter rodentium* ICC180Dr. S ClareN/A**Chemicals, Peptides, and Recombinant Proteins**Recombinant mouse GM-CSFPeprotechCat\#315-03Recombinant mouse M-CSFPeprotechCat\#315-02Recombinant human M-CSFPeprotechCat\#300-25Brefeldin AThermo Fisher ScientificCat\#00-4506-51LIVE/DEAD Fixable Aqua Dead Cell StainThermo Fisher ScientificCat\#L34957Dextran sodium sulfateMP BiomedicalsCat\#0216011080Percoll GE HealthcareSigma-AldrichCat\#17-0891-01Collagenase ASigma-AldrichCat\#10103578001DNase I from bovine pancreasRocheCat\#10104159001Wheat Germ Agglutinin, Alexa Fluor 594 conjugateThermo Fisher ScientificCat\#W112622-deoxy-D-glucoseSigma-AldrichCat\#D6134PureCol EZ GelSigma-AldrichCat\#5074**Critical Commercial Assays**Intracellular Fixation and Permeabilization Buffer SetThermo Fisher ScientificCat\#88-8824-00FoxP3 staining buffer setThermo Fisher ScientificCat\#00-5523-00High Capacity RNA-to-cDNA kitApplied BiosystemsCat\#4387406Mouse GM-CSF ELISA kitR&D systemsCat\#DY415-05Mouse IL-1β ELISA kitR&D systemsCat\#DY401-05Mouse IL-22 ELISA kitR&D systemsCat\#DY582-05Mouse PDGF-BB ELISA kitR&D systemsCat\#DY8464-05PureLink RNA Mini kitThermo Fisher ScientificCat\#12183025RNeasy Micro kitQIAGENCat\#74004ROX Low KAPPA Library Quantification kitKAPPA BiosystemsCat\#KK4873SMARTer stranded total RNA-Seq mammalian pico input kitTakaraCat\#635007TaqMan Fast Advanced Master MixThermo Fisher ScientificCat\#4444557TaqMan Gene Expression (18S rRNA)Thermo Fisher ScientificMm03928990_g1TaqMan Gene Expression (*Bhlhe40*)Thermo Fisher ScientificMm00478593_m1TaqMan Gene Expression (*Col4a1*)Thermo Fisher ScientificMm01210125_m1TaqMan Gene Expression (*Gapdh*)Thermo Fisher ScientificMm99999915_g1TaqMan Gene Expression (*H2-Aa*)Thermo Fisher ScientificMm00439211_m1TaqMan Gene Expression (*Hk2*)Thermo Fisher ScientificMm00443385_m1TaqMan Gene Expression (*Hprt*)Thermo Fisher ScientificMm03024075_m1TaqMan Gene Expression (*Il1b*)Thermo Fisher ScientificMm00434228_m1TaqMan Gene Expression (*Il6*)Thermo Fisher ScientificMm00446190_m1TaqMan Gene Expression (*Il10*)Thermo Fisher ScientificMm01288386_m1TaqMan Gene Expression (*Il18*)Thermo Fisher ScientificMm00434226_m1TaqMan Gene Expression (*Il23a*)Thermo Fisher ScientificMm00518984_m1TaqMan Gene Expression (*Nos2*)Thermo Fisher ScientificMm00518984_m1TaqMan Gene Expression (*Pdgfb*)Thermo Fisher ScientificMm00440677_m1TaqMan Gene Expression (*Reg3b*)Thermo Fisher ScientificMm00440616_g1TaqMan Gene Expression (*Reg3g*)Thermo Fisher ScientificMm00441127_m1TaqMan Gene Expression (*Slc2a1*)Thermo Fisher ScientificMm00441480_m1TaqMan Gene Expression (*Tgfbr2*)Thermo Fisher ScientificMm03024091_m1TaqMan Gene Expression (*Tnfsf15*)Thermo Fisher ScientificMm00770031_m1**Deposited Data**RNaseq data (colonic macrophages ± anti-CD90.2)This paperGEO: [GSE135492](ncbi-geo:GSE135492){#intref0145}RNaseq data (colonic tissue ± anti-CD90.2)This paperGEO: [GSE135792](ncbi-geo:GSE135792){#intref0150}RNaseq data (DSS macrophages)[@bib6]GEO: [GSE109040](ncbi-geo:GSE109040){#intref0155}RNaseq data (human ileal CD biopsies)[@bib36]GEO: [GSE93624](ncbi-geo:GSE93624){#intref0160}Single cell RNaseq (ileal Crohn's disease)[@bib37]GEO: [GSE134809](ncbi-geo:GSE134809){#intref0165}Single cell RNaseq (ulcerative colitis)[@bib60]<https://singlecell.broadinstitute.org/single_cell/study/SCP259>Single cell RNaseq (healthy colon)[@bib25]<https://www.gutcellatlas.org/>Single cell RNaseq (murine DSS colon)[@bib29]GEO: [GSE114374](ncbi-geo:GSE114374){#intref0180}Microarray data (human UC biopsies)[@bib70]GEO: [GSE59071](ncbi-geo:GSE59071){#intref0185}Microarray data (GM-CSF-treated BMDM)[@bib31]ArrayExpress: [E-MTAB-792](array-express:E-MTAB-792){#intref0190}Microarray data (Immgen Consortium Phase 2)VariousGEO: [GSE37448](ncbi-geo:GSE37448){#intref0195}Microarray data (human macrophage stimulations)[@bib75]GEO: [GSE47189](ncbi-geo:GSE47189){#intref0200}**Experimental Models: Cell Lines**Mouse: Immortalized lung fibroblastsJohn O'NeillN/A**Experimental Models: Organisms/Strains**Mouse: C57BL/6 (B6)Jackson LaboratoriesStock No: 000664Mouse: B6-GFP: C57BL/6-Tg(UBC-GFP)30Scha/JJackson LaboratoriesStock No: 004353Mouse: *Csf2rb*^*−/−*^: B6.*Csf2rb*^*−/−*^Fiona PowrieN/AMouse: CD45.1^*+*^: B6.SJL-*Ptprc*^*a*^*Pepc*^*b*^*/*BoyJJackson LaboratoriesStock No: 002014Mouse: *Rag2*^*−/−*^: B6(Cg)-*Rag2*^*tm1.Cgn*^/JJackson LaboratoriesStock No: 008449Mouse: *Rag1*^*−/−*^: B6.129S7-*Rag1*^*tm1Mom*^/JJackson LaboratoriesStock No: 002216Mouse: RORγt-EGFP: B6.RORγt-EGFPAndrew McKenzieN/A**Software and Algorithms**FlowJoTree Star Inc.<https://www.flowjo.com/>Gene Set Enrichment AnalysisBroad Institute<https://www.gsea-msigdb.org/gsea/>GraphPad Prism 6GraphPad Software<https://www.graphpad.com/>ImageJNational Institutes of Health<https://imagej.nih.gov/ij/>Ingenuity Pathway AnalysisQIAGEN<http://www.qiagen.com/cn/>**Other**123count eBeadsThermo Fisher ScientificCat\#01-1234-42

Resource Availability {#sec4.2}
---------------------

### Lead Contact {#sec4.2.1}

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Menna R. Clatworthy (<mrc38@cam.ac.uk>).

### Materials Availability {#sec4.2.2}

This study did not generate new unique reagents.

### Data and Code Availability {#sec4.2.3}

RNA sequencing datasets generated in this study have been deposited on Gene Expression Omnibus under accession codes [GSE135792](ncbi-geo:GSE135792){#intref0235} and [GSE135492](ncbi-geo:GSE135492){#intref0240}.

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

All mouse lines used here are on a C57BL/6J background. CD45.2^+^, CD45.1^+^, and *Rag2*^−/−^ and *Rag1*^*−/−*^ mice, and mice expressing EGFP under the control the of ubiquitin C promoter, were obtained from Jackson Laboratories (Margate, UK) and maintained inhouse for several generations. RORγt-EGFP mice were kindly provided by Andrew McKenzie (MRC-LMB, UK) and maintained in house for several generations. *Csf2rb*^*−/−*^ mice were kindly provided by Fiona Powrie (University of Oxford, UK). For the generation of bone marrow chimeras, recipient CD45.1/2^+^ C57BL/6 mice were lethally irradiated (2 × 5.5 G) followed by immediate tail intravenous (i.v.) injection of 2 × 10^6^ bone marrow cells from CD45.2^+^ *Csf2rb*^*−/−*^ (all chimeras), CD45.1^+^ *Csf2rb*^*+/+*^ (80:20 chimeras), or CD45.2^+^ *Csf2rb*^*+/+*^ (100% chimeras) mice. Recipient mice were checked for reconstitution after 8 weeks by tail vein bleed and flow cytometry on peripheral leukocytes prior to commencement of colitis experiments. For all *in vivo* colitis experiments, littermate mice were sex-matched within experiment and co-housed throughout. Both male and female 8-14 week old mice were used. Mice were maintained in specific pathogen-free conditions at a Home Office-approved facility in the UK, at the University of Cambridge or the Wellcome Trust Sanger Institute. All procedures were carried out in accordance with the United Kingdom Animals (Scientific Procedures) Act of 1986.

Method Details {#sec4.4}
--------------

### DSS-Induced Experimental Colitis {#sec4.4.1}

Colitis was induced the addition of 2% (*w/v*) 36,000-50,000 MW DSS (MP Biomedicals) to drinking water for 6-7 days, unless otherwise stated. Depleting/blocking antibodies were administered *in vivo* via i.p. injection (final volume, 200 mL sterile PBS). 0.25 mg InVivoMab anti-CD90.2 IgG (30H12; BioXCell) was given on days 0 and 3 of DSS protocol. 0.5 mg anti-GM-CSF IgG antibody (MP1-22E9; BioXCell) was injected on days −3, 0 and 3 of DSS protocol. InVivoMAb anti-KHL IgG (LTF-2; 2BScientific) was used as a control. Colitis severity was monitored daily through changes in body weight, stool consistency, and intestinal hemorrhage. Moderate severity limits were imposed, with 20% weight loss or two moribund characteristics judged to be the severity threshold. At experimental endpoints, colon, spleen, MLN and blood were harvested and colitis severity further assessed through morphological changes in organs. The spleen, MLN, and colon were weighed, and colon length measured from cecum to rectum to determine length. The tissues were then processed for histology, RNA extraction, or flow cytometric analysis.

### Citrobacter rodentium Infection {#sec4.4.2}

Mice were orally infected with 200 μL of *Citrobacter rodentium* ICC180 (10^9^ CFUs). At day 7-10, mice were sacrificed, and colon processed for downstream applications. For 100% chimera experiments, *C. rodentium* infection was prolonged until disease severity limits (20% weight loss) were achieved. Antibody dosing was carried out as described above. Caecum and liver were homogenized, and bacterial burden assessed by serial dilution, plating onto LB agar plates, and overnight incubation at 37°C.

### Murine Primary Cell Isolation {#sec4.4.3}

Spleen, mesenteric lymph nodes (MLN), and colon were harvested and processed for single cell suspensions. Colons were dissociated from fat and luminal contents were gently removed. Tissues were opened longitudinally, cut into 0.5 cm pieces and washed by vortexing in ice-cold PBS with 10 mM HEPES. Tissue pieces were subsequently incubated with a stripping solution (RPMI-1640 medium containing 2% (*v/v*) FCS, 10 mM HEPES, 1 mM DTT, and 5 mM EDTA) at 37°C for two intervals of 20 min to remove epithelial cells, prior to enzymatic digestion in RPMI-1640 medium containing 1 mg/ml collagenase A (Sigma Aldrich) and 60 mg/mL DNase I (Roche). Tissue suspensions were mechanically dissociated and passed through a 70 mm cell strainer. Intestinal single cell suspensions were then harvested at the interface of a 40/80% (*v/v*) Percoll (Sigma-Aldrich) gradient and washed thoroughly in ice-cold PBS containing 3% (*v/v*) FCS before proceeding to further analysis. MLN and spleen suspensions were harvested by enzymatic digestion and mechanical tissue dissociation through a 70 mm filter. Splenic suspensions were subjected to red blood cell lysis (distilled H~2~O containing 0.83% (*w/v*) NH~4~Cl, 0.1% (*w/v*) NaHCO~3~, 100 mM EDTA) prior to washing twice in ice-cold PBS for analysis.

Peripheral blood leukocytes were obtained by tail vein bleed into Microvette EDTA-coated tubes (Sarstedt). Red blood cells were lysed as above prior to washing twice in ice-cold PBS for subsequent downstream analysis.

### Flow Cytometry and Cell Sorting {#sec4.4.4}

Single cell suspensions were blocked for 20 min at 4°C with 0.5% (*v/v*) heat-inactivated mouse serum followed by extracellular staining for 30 min at 4°C with a combination of the following antibodies in 96-well plates. Murine antibodies: B220 (RA3-6B2, Thermo Fisher Scientific), CD3ε (145-2C11, Thermo Fisher Scientific), CD4 (GK1.5, Thermo Fisher Scientific), CD11b (M1/70, Thermo Fisher Scientific), CD11c (N418, Thermo Fisher Scientific), CD19 (6D5, Biolegend), CD45.1 (A20, Thermo Fisher Scientific), CD45.2 (104, Thermo Fisher Scientific), CD90.2 (30-H12, Thermo Fisher Scientific), CD117 (ACK2, Thermo Fisher Scientific), CD127 (A7R34, Biolegend), CX3CR1 (SA011F11, Biolegend), F4/80 (BM8, Thermo Fisher Scientific), Ly6C (HK1.4, Thermo Fisher Scientific), Ly6C/G (RB6-8C5, Thermo Fisher Scientific), MHC-II (M5/114.15.2, Thermo Fisher Scientific), TCR beta (H57-597, Thermo Fisher Scientific), and TCR gamma/delta (GL3, Biolegend). Antibodies were used at a dilution of 1:100-200 in PBS. Viability staining was performed with LIVE/DEAD Fixable Aqua Dead Cell Stain kit (Thermo Fisher Scientific) for 20 min at room temperature. For intracellular cytokine staining, cells were incubated in RPMI-1640 medium containing 10% FCS, 1X penicillin-streptomycin (both Sigma-Aldrich), and 1X Brefeldin A (Thermo Fisher Scientific) solution for 4 h at 37°C, prior to fixation and permeabilization using the Intracellular Fixation and Permeabilization Buffer Set (Thermo Fisher Scientific) as per the manufacturer's instructions. For chimera IL-17A and IL-22 staining, cells were additionally treated with 20 ng/ml PMA (Sigma Aldrich) and 1 μg/ml ionomycin (Sigma Aldrich) for 4 h at 37°C. Staining was carried out for 1 h at room temperature using a combination of the following antibodies: GM-CSF (MP1-22E9, BD biosciences), IL-17A (TC11- 18H10.1, Biolegend), IL-22 (IL22JOP, Thermo Fisher Scientific), and pro-IL-1β (NJTEN3, Thermo Fisher Scientific). All antibodies were used at a 1:100 dilution. For intracellular transcription factor staining, the FoxP3 staining buffer set (Thermo Fisher Scientific) was use according to the manufacturer's instructions. Staining was performed with the following antibodies for 1 h at room temperature: RORγt (Q31-378, BD biosciences) and GATA3 (TWAJ, Thermo Fisher Scientific). All antibodies were used at a 1:100 dilution. Cell counting was performed using 123count eBeads (Thermo Fisher Scientific). Flow cytometry data collection was performed on a Fortessa cytometer (BD biosciences) and data was analyzed using FlowJo software (Tree Star Inc.).

Murine intestinal macrophages were flow-sorted as live CD11b^+^ CX3CR1^+^ Ly6C^lo^ MHC-II^hi^ cells. Murine intestinal ILC3s were sorted as live CD45.2^int^ lineage (CD3, CD19, B220, CD11b, Gr-1, CD11c, TCRb, TCRgd)^-^ RORγt^+^ (using RORγt-GFP reporter mice) or live CD45.2^int^ lineage^-^ CD117^+^ CD127^+^ (using wild-type mice). Cell sorting was performed on iCyt Synergy (Sony Biotechnology Inc.), and MoFlo (Beckman Coulter) cell sorters. Data were analyzed using FlowJo software (Tree Star Inc.).

### Macrophage Cultures and Stimulation {#sec4.4.5}

For murine BMDMs, bone marrow was flushed from the femur and tibia of mice using ice-cold sterile PBS and the subsequent cell suspension treated with red cell lysis buffer. Treated cells were then washed in ice-cold sterile PBS. BMDMs were generated by incubation of bone marrow cells in RPMI-1640 medium containing 10% FCS and 1X penicillin-streptomycin (both Sigma-Aldrich) (referred to as complete RPMI (cRPMI)) supplemented with 100 ng/ml murine macrophage colony-stimulating factor (M-CSF; Peprotech). M-CSF-supplemented culture medium was replaced on day 3 and adherent BMDMs were harvested on day 5-6.

For cytokine stimulation experiments, plated BMDMs were stimulated with 20 ng/ml murine GM-CSF (Peprotech) or control media (cRPMI supplemented with 20 ng/ml M-CSF) for 16 h. For macrophage-ILC3 co-cultures, 2.5-5 × 10^4^ BMDMs were plates in flat-bottomed 96-well plates (Sigma-Aldrich) in cRPMI supplemented with 20 ng/ml M-CSF overnight before co-culture with flow-sorted intestinal ILC3s (2:1 ratio of macrophages:ILC3s) or ILC3-conditoned media. After 24-72 h, cells were harvested or used for downstream assays. ILC3-conditioned media was generated by culture of ILC3s in cRPMI supplemented with 50 ng/ml murine IL-1β (Peprotech) for 16 h at a concentration of 1 × 10^6^ ILC3s/ml cRPMI. cRPMI supplemented with IL-1β was used as a control in these experiments.

### Commensal Microbe Phagocytosis {#sec4.4.6}

For commensal labeling, faecal content was extruded from the colon of WT mice, mechanically homogenized in PBS and vortexed for 5 min to break up clumps. Large remaining pieces were spun down in a desktop centrifuge for 20 s at 3,000 rpm and supernatant passed through a 30 μm cell filter to obtain a crude commensal bacteria extract. Commensal bacteria were then washed in PBS three times by spinning in a large centrifuge at 4,200 rpm for 10 min. Bacteria were fixed with 2.5% PFA at RT for 10 min, spun down and resuspended in 0.1% Triton X-100 in PBS for 10 mins at RT. Bacteria were labeled by incubating with 100 μg/ml Wheat Germ Agglutinin, Alexa Fluor 594 conjugate (W11262, Thermo Fisher Scientific) for 6 h at RT, washed thoroughly, and post-fixed for 10 min in 2.5% PFA at RT, and resuspended in 1 mL PBS before use in phagocytosis assays. For phagocytosis assays, BMDMs or colonic lamina propria cells were incubated with 1/100 dilution of the fluorescently labeled commensal bacterial extract for 30 min. Cells were then washed 3 times in PBS before downstream flow cytometry analysis.

### Macrophage Commensal Stimulation {#sec4.4.7}

2.5 × 10^5^ BMDMs were seeded into 24-well plates and stimulated with GM-CSF or control media as indicated above for 24 h. Murine faecal commensal suspensions were prepared from a 100 mg/ml stool sample in PBS and processed as above. BMDMs were then stimulated with 1:100 dilution of crude commensal suspension for 6 h and supernatants collected for cytokine analysis. For 2-deoxy-D-glucose assays (2DG), BMDMs were pre-treated for 1 h with 1 mM 2DG (Sigma Aldrich) prior to commensal stimulation.

### Macrophage Motility Assay {#sec4.4.8}

For analyzing BMDM seek behavior, 0.5 × 10^6^ BMDMs stimulated for 24 hr with 20 ng/ml GM-CSF or 50 ng/ml M-CSF from EGFP-ubiquitin mice were re-suspended in 100 μL of cRPMI and mixed with 200 μL PureCol EZ Gel (5074, Sigma-Aldrich). The collagen cell mix was then applied to a three-sided chamber on a microscopy slide, created by sealing with paraffin wax and covering with a glass slip. The microscopy slide was then incubated upright in a 5% CO~2,~ 37°C incubator for 1 h to allow the collagen gel to set. 250 μL of cRPMI was then layered on top of the collagen gel inside the chamber, the remaining side sealed with paraffin wax and slide taken immediately to a TCS SP8 (Leica) microscope containing a 37°C pre-heated imaging chamber for imaging of BMDM seek behavior over the space of 1 h. Seek behavior videos were processed and quantified using Imaris software.

### Fibroblast Wound Scratch Assay {#sec4.4.9}

Murine immortalized lung fibroblasts, a gift from John O'Neill (MRC-LMB, Cambridge, UK) were seeded at 4 × 10^4^ cells per well into 96-well flat-bottomed plates overnight and subsequently scratched once with a p200 pipette tip. Scratched fibroblasts were washed in DMEM and subsequently incubated with macrophage-conditioned DMEM medium or DMEM supplemented with 20 ng/ml recombinant murine PDGF-BB (Peprotech). Scratched fibroblasts were imaged at 4 h intervals for 24 h on an IncuCyte S3 (Essen Bioscience) to monitor wound closure. Macrophage-conditioned medium was generated by incubation of control or GM-CSF-primed BMDMs in fresh DMEM medium for 4 h. Image analysis was performed in ImageJ.

### Metabolic Assays {#sec4.4.10}

7 × 10^4^ BMDMs per well were seeded into standard Seahorse 96-well plates and cultured with ILC3-conditioned cRPMI or control cRPMI ± anti-GM-CSF IgG (BioXCell) for 16 h. Media was changed prior to analysis for glucose-free XF base media (Seahorse Biosciences) supplemented with 2 mM sodium pyruvate (Thermo Fisher Scientific) and 1X glutamax (Thermo Fisher Scientific). Perturbation of metabolic pathways was achieved by addition of glucose (10 mM), oligomycin (1 μM), and 2-deoxy-D-glucose (100 mM) (Sigma-Aldrich) and data collected on a Seahorse XFp Analyzer (Agilent Technologies).

### RNA Extraction and Reverse Transcription {#sec4.4.11}

RNA extraction was carried out using commercially available kits as per the manufacturer's instructions. QIAGEN RNeasy micro kits were used for cell numbers below 5 × 10^5^. The PureLink RNA mini kit (Thermo Fisher Scientific) was used for cell numbers over 5 × 10^5^. For whole tissue RNA extraction, tissue pieces were first disrupted using a Precellys 24 Homogenizer (Bertin Instruments), before extraction using the PureLink RNA mini kit (Thermo Fisher Scientific). RNA concentration and purity were determined using a NanoDrop spectrophotometer (Thermo Scientific) prior to cDNA synthesis using a High-Capacity RNA-to-cDNA kit (Applied Biosystems).

### Quantitative Polymerase Chain Reaction {#sec4.4.12}

All qPCR was carried out in triplicate in a final volume of 10 μL in a 384-well plate with Taqman reagents and the following pre-designed TaqMan Gene Expression Assay primers and probes (Thermo Fisher Scientific). Murine primers: 18S rRNA (Mm03928990_g1), *Bhlhe40* (Mm00478593_m1), *Col4a1* (Mm01210125_m1), *Gapdh* (Mm99999915_g1), *H2-Aa* (Mm00439211_m1), *Hk2* (Mm00443385_m1), *Hprt* (Mm03024075_m1), *Il1b* (Mm00434228_m1), *Il6* (Mm00446190_m1), *Il10* (Mm01288386_m1), *Il18* (Mm00434226_m1), *Il23a* (Mm00518984_m1), *Nos2* (Mm00440502_m1), *Pdgfb* (Mm00440677_m1), *Reg3b* (Mm00440616_g1), *Reg3g* (Mm00441127_m1), *Slc2a1* (Mm00441480_m1), *Tgfbr2* (Mm03024091_m1), and *Tnfsf15* (Mm00770031_m1). qPCR was carried performed on the Viia 7 PCR machine (Life Technologies). Gene expression was normalized to *Gapdh*, *Hprt*, or 18S rRNA using the 2^-ΔCt^. The 2^-ΔΔCt^ method was used for normalization between experimental conditions and genotypes.

### ELISA {#sec4.4.13}

Quantification of murine cytokines and PDGF-BB in culture supernatants was carried out using commercially available R&D systems Duoset ELISA kits, as per the manufacturer's instructions. Optical densities were measured at 450 nm and 530 nm background using a CLARIOstar spectrophotometer (BMG Labtech).

### RNaseq Sample Preparation {#sec4.4.14}

*Macrophage RNASeq:* Flow-sorted colonic CX3CR1^+^ CD11b^+^ Ly6C^lo^ MHC-II^+^ macrophages were immediately lysed in 750 μL RLT plus buffer (QIAGEN). Samples were vortexed, snap frozen on dry ice and stored at −80°C. RNA was extracted from cell lysates using the RNeasy plus micro kit (QIAGEN) as per the manufacturer's instructions. Optimal DNA depletion columns (QIAGEN) were used to remove contaminating genomic DNA. Purified RNA was eluted in nuclease free water (Ambion) and stored at −80°C. Quality and concentration of the purified RNA was assessed using an RNA pico chip (Applied Biosystems) using a Bioanalyzer 2000 (Applied Biosystems) as per the manufacturer's instructions. For all RNaseq experiments, samples had an RNA integrity number \> 8. For the preparation of libraries, SMARTer stranded total RNaseq mammalian pico input kit (Takara) was used as per the manufacturer's instructions. To produce the libraries, 5ng of total RNA was used.

*Colon RNASeq:* RNA was extracted using the PureLink RNA mini kit and contaminating DNA digested with TurboDNase (Invitrogen). Quality of RNA was checked as above. RNASeq librarys were prepared using Illumina TruSeq Stranded total RNA library prep kit wuth 1ug of RNA as per manufactuers instructions.

Library size was assessed with a High Sensitivity DNA chip (Applied Biosystems) using a Bioanalyzer 2000 (Applied Biosystems) as per the manufacturer's instructions. Library concentration was quantified by PCR with ROX low KAPPA library quantification kit (KAPPA Biosystems). Libraries were pooled at an equimolar concentration with up to 10 libraries per pool.

### RNA Sequencing and Analysis {#sec4.4.15}

Sequencing of the Colon RNASeq was carried out using a Novaseq 6000 (Illumina) and the Macrophage RNaseq on a Hiseq 4000 both on a 2x150bp sequencing run. Sequencing was carried out at Genewiz (NJ, USA). Pooled libraries were de-multiplexed by Genewiz using Casava (Illumina) before transfer of the data to the University of Cambridge. The Fastq files from libraries prepared using the Takara library prep were were trimmed of the first 3 nucleotides of the R1 strand and contaminating adaptor sequences and poor-quality bases removed (bases with a phred 33 score of \< 30) using trimgalore! (Babraham bioinformatics). The Illumina library preps were only trimmed for quality. Sequencing quality of the resulting files was assessed using FastQC (Babraham bioinformatics). Fastq files were aligned to the mm10 genome using hisat2. Subsequent analysis was carried out in R. Reads were counted and assigned to genes using the Featurecount function from the RSubread package. Differential expression analysis was carried out using DESeq 2 using a linear model with an appropriate design matrix following the default workflow. Resulting figures were plotted using ggplot2 and pheatmap. GSEA was performed for RNaseq data by first assigning a rank metric to each gene using the following formula:$$\text{Rank}\ \text{metric} = 1\left( {P\text{value} + 1 \times 10^{- 300}} \right) \ast \left( {\left| \text{LFC} \right|/\text{LFC}} \right)$$GSEA was then run using GSEA 4.0.1 using the pre-ranked option with the classic setting against either gene sets from the molecular signature database or custom 100/200-gene gene sets indicated in the text. STRING analysis was performed using the online portal (<https://string-db.org>) selecting high-highest confidence parameters (0.700-0.900) with no additional interactors, unless stated in the text.

### Public RNaseq and Microarray {#sec4.4.16}

Publicly available RNaseq and microarray datasets were downloaded from GEO (<https://www.ncbi.nlm.nih.gov/geo/>) or ArrayExpress (<https://www.ebi.ac.uk/arrayexpress>) along with appropriate chip annotation data. All analyses were carried out using R. All datasets were downloaded as raw intensity matrices. For microarray analysis, data was normalized using RMA and limma. Probes were reduced to one probe per gene by selecting the probe with the greatest variance across the samples using the gene filter package. Differential expression was varied out using limma with an appropriate design matrix.

Public bulk transcriptomics datasets used in this study are as follows: GEO: [GSE47189](ncbi-geo:GSE47189){#intref0260} (Human macrophage stimulations) ([@bib75]); GEO: [GSE93624](ncbi-geo:GSE93624){#intref0265} (mucosal biopsies from ileal Crohn's disease) ([@bib36]); GEO: [GSE59071](ncbi-geo:GSE59071){#intref0270} (mucosal biopsies from ulcerative colitis) ([@bib70]); ArrayExpress: [E-MTAB-792](array-express:E-MTAB-792){#intref0275} (BMDMs treated with GM-CSF for 24 h) ([@bib31]); GEO: [GSE109040](ncbi-geo:GSE109040){#intref0280} (colonic murine macrophages from control or DSS-treated mice) ([@bib6]); GEO: [GSE37448](ncbi-geo:GSE37448){#intref0285} (Immgen Consortium Phase 2).

### Single Cell RNaseq {#sec4.4.17}

For ulcerative colitis and healthy colonic scRNaseq analysis, count matrices were downloaded from the Broad Single Cell Portal (<https://singlecell.broadinstitute.org/single_cell/study/SCP259>) ([@bib60]) and <https://www.gutcellatlas.org/> ([@bib25]). Data were normalized and log transformed using the Scanpy tool ([@bib72]). Immune cell data were split by health status or sampling site, and cell type and gene expression values plotted using ggplot2 tools in R.

For ileal CD, single cell RNaseq was extracted from GEO: [GSE134809](ncbi-geo:GSE134809){#intref0300} ([@bib37]). The single-cell data (10x *cellranger* output) was processed using standard *Seurat*-inspired *scanpy* workflow ([@bib63]; [@bib72]) with standard quality control steps; cells were filtered if number of genes \> 2500 or \< 200 and percentage mitochondrial content \> = 5%. Genes were retained if is expressed by at least 3 cells. Doublet detection was performed using *scrublet* ([@bib73]) with adaptations outlined in ([@bib45]). Batch correction was performed using *bbknn* with samples (patient/donor) as the batch term ([@bib44]). Clustering was performed using Leiden algorithm ([@bib66]). To group clusters into either resident macrophages or infiltrating monocyte/macrophages and DCs, marker genes were selected based on the original paper. Wilcoxon test implemented in *Scanpy (rank_genes_groups)* was performed to extract the list of significant differentially expressed genes between infiltrating and resident macrophages. for IPA analysis.

For murine gut stromal scRNaseq analysis, expression matrices from [GSE114374](ncbi-geo:GSE114374){#intref0305} were acquired from GEO ([@bib29]). Highly variable genes were called using the Scanpy workflow in python, setting min_mean = 0.01, max_mean = 8, and min_disp = 1 ([@bib72]). The expression matrix was subsetted to highly variable genes, before computing dimensionality reduced coordinates using principal components analysis. We used these coordinates to generate a UMAP embedding, and clustered the resulting neighbor graph using Leiden clustering ([@bib66]), setting resolution = 0.5. Consequently, we were able to manually annotate clusters to the cell types identified in [@bib29] on the basis of canonical marker expression as described in their paper. We calculated marker gene sets for each annotated cell type using the tf-idf metric and computed p values using hypergeometric testing ([@bib76]).

### Ingenuity Pathway Analysis {#sec4.4.18}

Ingenuity Pathway Analysis (IPA) was performed using the following settings were used for all samples: Ingenuity knowledge database (Genes only); direct and indirect relationships; 35 molecules per network and 25 networks per analysis; all nodes and datasources; experimentally observed confidence setting; and all species, tissues and cell lines, and mutations. Customised settings for each dataset was used to sample between 500-1000 genes. For DSS-macrophages: minimum expression = 10; fold change = 1.5; adjusted *P value* = 0.05. For αCD90.2 macrophages: minimum expression = 10; fold change = 1.0; adjusted *P value* = 0.05. For ileal Crohn's disease scRNaseq: fold change = 2; adjusted *P value* = 0.05. For upstream regulators, all observations biased observations were excluded and bias-corrected regulation z-score and *P value* of overlap statistics used.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

Statistical analysis was performed using GraphPad Prism software, R, IPA, or GSEA. For *in vivo* colitis experiments, comparison between experimental groups was performed using a nonparametric Mann-Whitney-U test, unless otherwise stated, and medians are indicated. For *in vitro* stimulation experiments, mean ± standard error of mean (SEM) are shown and a parametric Student's two-tailed t test, and one-way or two-way ANOVA with Tukey's multiple comparisons test was used, unless paired samples were used, where a paired t test was used. For RNaseq bioinformatics analyses, *P value*s were calculated using the standard DESeq 2 method with multiple correction using BH procedure. For microarray experiments, *P value*s were calculated using the limma package with multiple correction using BH procedure. ^∗^ p \< 0.05; ^∗∗^ p \< 0.01; ^∗∗∗^ p \< 0.001; ^∗∗∗∗^ p \< 0.0001. Sample sizes (*n*) for all shown data can be found in figure legends. *In vitro* stimulations were performed in triplicate, unless stated, and sample sizes for *in vivo* experiments were determined based on initial experiments.
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